AVDL Key Statistics, Chart & Performance
The current stock price of AVDL is 21.52 USD. In the past month the price increased by 0.75%. In the past year, price increased by 94.58%.
AVDL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.13 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.98 | 499.57B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.87 | 143.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.15 | 108.83B | ||
| ZTS | ZOETIS INC | 19.86 | 55.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.45 | 22.43B | ||
| VTRS | VIATRIS INC | 5.35 | 14.35B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.46 | 11.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.01B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.56B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.43B |
Related stock screener links
About AVDL
Company Profile
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Company Info
AVADEL PHARMACEUTICALS
Block 10-1 Blanchardstown Corporate Park, Ballycoolin
DUBLIN DUBLIN D02 IE
CEO: Gregory J. Divis
Employees: 188
Phone: 35319015201
AVADEL PHARMACEUTICALS / AVDL FAQ
Can you describe the business of AVADEL PHARMACEUTICALS?
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 188 full-time employees. The firm's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
What is the stock price of AVADEL PHARMACEUTICALS today?
The current stock price of AVDL is 21.52 USD. The price decreased by -0.14% in the last trading session.
Does AVADEL PHARMACEUTICALS pay dividends?
AVDL does not pay a dividend.
How is the ChartMill rating for AVADEL PHARMACEUTICALS?
AVDL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does AVADEL PHARMACEUTICALS belong to?
AVADEL PHARMACEUTICALS (AVDL) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the number of employees for AVADEL PHARMACEUTICALS?
AVADEL PHARMACEUTICALS (AVDL) currently has 188 employees.
Can you provide the ownership details for AVDL stock?
You can find the ownership structure of AVADEL PHARMACEUTICALS (AVDL) on the Ownership tab.
AVDL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AVDL. When comparing the yearly performance of all stocks, AVDL is one of the better performing stocks in the market, outperforming 95.87% of all stocks.
AVDL Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AVDL. AVDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AVDL Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| Debt/Equity | 0.35 |
AVDL Forecast & Estimates
16 analysts have analysed AVDL and the average price target is 21.48 USD. This implies a price decrease of -0.2% is expected in the next year compared to the current price of 21.52.
For the next year, analysts expect an EPS growth of 138.39% and a revenue growth 62.59% for AVDL